Group 1 - The Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Capricor Therapeutics, Inc. securities between October 9, 2024, and July 10, 2025 [1] - Investors who purchased Capricor securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by September 15, 2025, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - The misleading statements led to shareholders purchasing Capricor's securities at artificially inflated prices, resulting in damages when the true information was revealed [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Replimune Group, Inc. securities for the period between November 22, 2024, and July 21, 2025, due to alleged misleading statements regarding the IGNYTE trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the IGNYTE trial's prospects, which led to the FDA deeming the trial inadequate [5]. - Investors who purchased Replimune securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. - The lawsuit claims that throughout the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole and its efficacy for treating bipolar disorder, which negatively impacted the company's business and financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Alto Neuroscience, Inc. common stock, alleging that the company made materially false and misleading statements regarding its business and prospects during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Alto's offering documents contained false statements about the effectiveness of ALTO-100 in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 19, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Vestis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

Core Viewpoint - A class action lawsuit has been filed against Broadmark Realty Capital Inc. regarding the merger with Ready Capital Corporation, alleging misleading statements in the proxy statement used to solicit shareholder support for the merger [1][5]. Group 1: Lawsuit Details - The lawsuit claims that the proxy statement contained false or misleading statements and failed to disclose significant financial distress among borrowers in Ready Capital's portfolio due to high interest rates [5]. - It is alleged that an oversupply of multifamily properties limited the ability of Ready Capital borrowers to raise rents to cover growing debt costs [5]. - A major development project acquired during the merger, valued at approximately $500 million, faced catastrophic setbacks, including cost overruns and funding shortfalls [5]. - The lawsuit asserts that Ready Capital's expected credit loss reserves were materially understated, impacting financial projections regarding distributable earnings, dividends, and book value per share [5]. Group 2: Participation Information - Individuals who held Broadmark common stock as of the merger date may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm for more information [3][6].

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Vestis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2025. SO WHAT: If you purchased Neogen common stock during the Class Period you may be entitled to comp ...

NEW YORK, July 21, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2025.So What: If you purchased Capricor securities during the ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Red Cat Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 22, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Red Cat securities between March 18, 2022, and January 15, 2025, may be eligible for compensation through a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to participate [2][5]. - The lawsuit alleges that Red Cat made false and misleading statements regarding its production capacity and the value of its contracts, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].